Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of “Buy” from Analysts

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have received a consensus rating of “Buy” from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $30.00.

Several research firms recently commented on ATXS. Wedbush restated an “outperform” rating and issued a $28.00 target price (up from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a report on Tuesday, March 11th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $47.00 price objective on shares of Astria Therapeutics in a research note on Wednesday, May 14th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ATXS. KLP Kapitalforvaltning AS acquired a new stake in Astria Therapeutics in the 4th quarter valued at about $41,000. Tower Research Capital LLC TRC lifted its stake in Astria Therapeutics by 109.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 2,766 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in Astria Therapeutics during the fourth quarter worth approximately $50,000. Virtus ETF Advisers LLC acquired a new position in Astria Therapeutics in the fourth quarter worth approximately $65,000. Finally, GAMMA Investing LLC increased its holdings in shares of Astria Therapeutics by 1,127.4% in the first quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 7,971 shares in the last quarter. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Stock Performance

ATXS stock opened at $5.79 on Thursday. Astria Therapeutics has a 1 year low of $3.56 and a 1 year high of $12.92. The stock has a market capitalization of $326.75 million, a price-to-earnings ratio of -2.77 and a beta of 0.39. The stock’s fifty day moving average is $4.55 and its two-hundred day moving average is $6.65.

Astria Therapeutics (NASDAQ:ATXS) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.10). As a group, analysts predict that Astria Therapeutics will post -1.65 EPS for the current fiscal year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.